Knight Therapeutics (TSX:GUD) Debt-to-Equity : 0.09 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Debt-to-Equity?

Knight Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$19.6 Mil. Knight Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$49.5 Mil. Knight Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$746.9 Mil. Knight Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Knight Therapeutics's Debt-to-Equity or its related term are showing as below:

TSX:GUD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.08 Max: 0.09
Current: 0.09

During the past 11 years, the highest Debt-to-Equity Ratio of Knight Therapeutics was 0.09. The lowest was 0.05. And the median was 0.08.

TSX:GUD's Debt-to-Equity is ranked better than
74.59% of 854 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs TSX:GUD: 0.09

Knight Therapeutics Debt-to-Equity Historical Data

The historical data trend for Knight Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Debt-to-Equity Chart

Knight Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.08

0.06

0.05

0.09

Knight Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.09	0.10	0.10	0.10	0.09

Competitive Comparison of Knight Therapeutics's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Knight Therapeutics's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Debt-to-Equity falls into.

Knight Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Knight Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(19.578	+	49.513)	/	746.871
	=	0.09

Knight Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(19.578	+	49.513)	/	746.871
	=	0.09

Knight Therapeutics (TSX:GUD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Knight Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Knight Therapeutics (TSX:GUD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

KHTRF:USA

Address

3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8

Website

https://www.gud-knight.com

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Executives

Sime Armoyan

10% Security Holder

Knight Therapeutics (TSX:GUD) Headlines

No Headlines